Navigation Links
KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE
Date:2/15/2008

Fiscal 2007 Marked Record Profitability and 12th Consecutive Year of Record

Revenues KV Also Reports Preliminary Fiscal 2008 Third Quarter Revenues of $164

Million, Up 39% from Prior Year

ST. LOUIS, Feb. 15 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology-differentiated branded and generic/non-branded prescription pharmaceutical products, reported today its consolidated results of operations for the 2007 fiscal year ended March 31, 2007. The results have been delayed primarily due to the previously reported investigation by a Special Committee of independent members of the Board of Directors into the Company's former stock option grant practices.

KV is nearing completion of work to restate financial results for the periods affected. In addition to the fiscal 2007 results, KV has also included the following items with today's release:
-- restated consolidated results for fiscal years 2005 and 2006;

-- balance sheets as of March 31, 2007 and March 31, 2006 (as restated);

-- a reconciliation of the income statements as restated for fiscal years

2005 and 2006 and the income statements as originally reported; and

-- a reconciliation of the year-end 2006 balance sheet as restated

compared to the year-end 2006 balance sheet as originally reported.

The Company also announced that NYSE Regulation, Inc. today granted the Company's request for a trading extension through March 31, 2008, subject to ongoing reassessment. The extension was required under the Exchange's rules due to the Company's delayed filing of its fiscal 2007 Annual Report on Form 10-K with the Securities and Exchange Commission. The Company expects to have resolved all outstanding issues needed to make this filing and to complete its fiscal 2007 f
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine news :

1. His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States
2. Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
3. NUCRYST Pharmaceuticals announces year-end results
4. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
5. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
6. Watson Pharmaceuticals Announces FDA Inspection of Florida Facilities
7. Convera(R) Expands Advanstar OnLine Business to Vertical Search Covering Pharmaceutical Industry Applications
8. American Association of Clinical Endocrinologists and North American Menopause Society Fail to Disclose Financial Ties to Wyeth Pharmaceuticals
9. Chesapeake to Expand and Relocate North American Pharmaceutical Packaging Operation
10. MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product
11. Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... health officials on Monday officially tightened guidelines for health workers ... skin exposure and use of a respirator at all times. ... to issue the tougher rules after two Dallas nurses contracted ... the United States, Liberian national Thomas Eric Duncan. Nina Pham ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 The ... the must-have source of thousands of facts, figures and ... countries and 68 medical sector forecast categories the ... with global, regional and national views on the worldwide ... outlook. , The report gives you data for 2010-2019, ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute ... to repair a damaged mitral valve as the heart ... developed by Abbott Vascular , is designed to ... condition in which the heart’s mitral valve leaflets fail ... the heart’s left ventricle into the left atrium. The ...
(Date:10/20/2014)... York, NY (PRWEB) October 20, 2014 ... based non-profit organization that helps New Yorkers living ... positive changes toward health, housing, recovery and self-sufficiency. ... have transformed the local community through their tireless ... Director, Marc Shapses , has been selected ...
(Date:10/20/2014)... T.E.N., a technology and information security ... William H. Murray, renowned author and industry visionary, ... Award winner. Presented annually, the ISE® Luminary Leadership ... and industry practitioner for his or her distinguished ... security industry. , Formerly with IBM, Murray is ...
Breaking Medicine News(10 mins):Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... , WEDNESDAY, July 20 (HealthDay News) -- Premature ... as teenagers, including attention deficit hyperactivity and depression, a ... the result of brain injuries affecting cortical development as ... Columbia University Medical Center. Although "preemies" are at ...
... In the fight to improve global health, alleviate hunger, ... world, chickens have an important role to play. ... for Infectious Diseases and Vaccinology at Arizona State University,s ... more productive species of chicken for villagers in rural ...
... of Minnesota Medical School researchers have developed a new strategy ... Currently, iPS cells are created by introducing four defined ... cell into a stem cell, which can differentiate into many ... four genes introduced are Oct4, Sox2, Klf4 and c-Myc, a ...
... dramatically among young people, it is deadly if not caught ... adapt to even the most modern therapies, known as VEGF ... discovery about proteins that underlie and stimulate the disease, opening ... This month in the journal Cancer Research , ...
... BOSTON Beth Israel Deaconess Medical Center (BIDMC) has ... Allergy and Infectious Diseases (NIAID), part of the National ... Vaccine Research in Nonhuman Primates. The five-year grant totals ... H. Barouch, MD, PhD, a Professor of Medicine at ...
... Bristol-Myers Squibb Company announced results from a long-term, ... (ARV)-experienced patients (336 female and 958 male) from ... at the Sixth International AIDS Society Conference on ... In a gender-specific sub-analysis, boosted REYATAZ (atazanavir sulphate) ...
Cached Medicine News:Health News:Preemies at Risk for Psychiatric Disorders as Teens, Study Contends 2Health News:A new breed: Highly productive chickens help raise Ugandans from poverty 2Health News:A new breed: Highly productive chickens help raise Ugandans from poverty 3Health News:U of M researchers improve method to create induced pluripotent stem cells 2Health News:URMC researchers exploring keys to melanoma progression 2Health News:URMC researchers exploring keys to melanoma progression 3Health News:In the real life setting, boosted REYATAZ proves as effective in women living with HIV as men 2
(Date:10/22/2014)... MOUNTAIN VIEW, Calif. , Oct. 22, ... 11:00 a.m. EDTLOCATION: Online, complimentary registration available ... Group Team Leader Archana Vidyasekar and Visionary ... VargheseBrain-controlled computers, WiFi-like wireless electricity, self-assembling materials, ... top ten technologies which will transform our ...
(Date:10/22/2014)... 2014  AcelRx Pharmaceuticals, Inc. (NASDAQ: ... IAP310 study have been published in Regional ... journal with broad, multidisciplinary readership. IAP310 was a ... and efficacy of Zalviso, also referred to as ... treatment of post-operative pain in patients following open ...
(Date:10/22/2014)... CAMBRIDGE, Mass. and SHANGHAI ... Inc. (NASDAQ: FMI ) and WuXi ... announced a collaboration to offer Foundation Medicine,s comprehensive genomic ... China . Under the ... enable WuXi to perform the laboratory component of Foundation ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5
... Inc. (Inspiration) announced today that the European Commission has ... of hemophilia.  Expected to enter pivotal clinical trials before ... treat individuals with hemophilia who have developed inhibitors against ... trigger a 10-year market exclusivity for OBI-1 in the ...
... DIEGO, Oct. 19 Aethlon Medical, Inc. (OTC Bulletin ... therapeutic filtration devices to address infectious disease and cancer, ... the Aethlon Medical board of directors. ... ) Mr. Kenley has 33 years of ...
Cached Medicine Technology:Inspiration Biopharmaceuticals' OBI-1 Receives Orphan Drug Designation in Europe 2Inspiration Biopharmaceuticals' OBI-1 Receives Orphan Drug Designation in Europe 3Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors 2Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors 3Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors 4Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors 5
... Merocel Ophthalmic Products ... superior fiber free products ... and safe cleaning of ... exclusive Merocel material is ...
... Ophthalmic Products are constructed of ... lint-free MEROCEL polyvinyl acetal sponge. ... be beneficial to both surgeon ... and yet firm enough to ...
... Ophthalmic Products are constructed of ... lint-free MEROCEL polyvinyl acetal sponge. ... be beneficial to both surgeon ... and yet firm enough to ...
Weck-Cel Triangle shaped spearhead, set on a malleable, polypropylene handle, is designed for use in delicate, surgical areas. Maintains rigidity during wicking process. Single use, packaged sterile....
Medicine Products: